XOMA Royalty Corporation (NASDAQ:XOMA) Given Consensus Recommendation of “Hold” by Brokerages

XOMA Royalty Corporation (NASDAQ:XOMA) has received an average recommendation of “Hold” from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $53.75.

Several analysts have commented on the company. TD Cowen upgraded XOMA Royalty to a “hold” rating in a report on Friday, February 13th. Zacks Research raised shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. HC Wainwright downgraded shares of XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 target price for the company. in a report on Thursday, April 30th. Leerink Partners reaffirmed an “outperform” rating on shares of XOMA Royalty in a research report on Tuesday, February 24th. Finally, Lucid Cap Mkts lowered shares of XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th.

XOMA Royalty Price Performance

XOMA stock opened at $41.89 on Friday. The stock has a market capitalization of $499.33 million, a price-to-earnings ratio of 28.69 and a beta of 0.90. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 1.15. XOMA Royalty has a 52-week low of $22.29 and a 52-week high of $42.81. The stock’s fifty day simple moving average is $33.03 and its 200-day simple moving average is $30.27.

XOMA Royalty (NASDAQ:XOMA) last released its earnings results on Wednesday, March 18th. The biotechnology company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.16. XOMA Royalty had a return on equity of 10.32% and a net margin of 45.75%.The firm had revenue of $13.76 million during the quarter, compared to analyst estimates of $11.13 million. Equities research analysts expect that XOMA Royalty will post 0.94 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Man Group plc purchased a new stake in XOMA Royalty during the third quarter valued at about $247,000. Squarepoint Ops LLC purchased a new position in shares of XOMA Royalty in the 4th quarter worth about $237,000. BNP Paribas Financial Markets lifted its stake in shares of XOMA Royalty by 266.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 2,346 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of XOMA Royalty in the 2nd quarter valued at about $116,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 543 shares during the period. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.